• Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

DEA Extends Telehealth Prescribing Exemptions As Public Health Emergency Ends

Article

The federal government is extending pandemic-era “flexibility” for telehealth prescriptions.

When the COVID-19 pandemic hit the United States in early 2020, the Drug Enforcement Agency (DEA) announced a set of waivers to make it easier for healthcare providers to prescribe controlled substances via telehealth consultations. The changes exempted providers from key provisions of the Ryan Haight Online Pharmacy Consumer Protection Act, a 2008 law designed to stop providers from writing prescriptions without a meaningful examination of patients. Those exceptions were set when the government’s official public health emergency ended on May 11.

But just before that deadline, the DEA announced a temporary extension of the pandemic waivers. The agency said it would allow the current exceptions to the Ryan Haight Act to continue for another six months, through November 11. The agency also announced an additional one-year grace period for cases where a provider-patient relationship is initiated prior to the November 11 deadline. That means patients who receive prescriptions for controlled substances based on telemedicine visits can continue receiving those prescriptions without an in-person visit to their prescriber through November 11, 2024, provided the provider-patient relationship begins before November 11.

One reason for the delay is the massive amount of public comment on the topic. The DEA said it had received 38,369 public comments on its proposed rules. The agency said it needs time to “closely review” those submissions.

Kyle Zelby, executive director of the ATA Action, the lobbying arm of the American Telemedicine Association.

Kyle Zelby, executive director of the ATA Action, the lobbying arm of the American Telemedicine Association.

The American Telemedicine Association (ATA) hailed the extension, calling it a “reprieve” for telehealth, and an opportunity for the agency to reconsider proposed permanent rules, which the association believes would be too restrictive.

“We are hopeful that during this extension period, the DEA will revise the draft rules to address unnecessarily restrictive barriers to equitable and appropriate clinical care, such as mandating in-person visits,” said Kyle Zebley, the executive director of the ATA’s lobbying arm, ATA Action.

Related Videos
Video 11 - "Closing Current Gaps within Fertility Benefits and Care"
Video 10 - "Shaping Fertility Coverage: Access, Costs & Medical Needs"
Video 9 - "Denial of Coverage in Fertility Care"
Video 8 - "Risks of Miscarriage and Multiple Births Associated with Fertility Care"
Video 7 - "Fertility Preservation: Egg Freezing Versus Embryo Freezing"
Video 6 - "Family Building Costs, Barriers, and Dropout Rates Associated with Fertility Care"
Video 5 - "Closing Payer Gaps and Improving Fertility Care Access"
Video 4 - "Increasing Employer Coverage and Maximizing Fertility Benefits "
Video 5 - "Relevance of NUTURE Study Findings for Patients, Payers, Providers"
Video 3 - "Improving IVF Success Rates & Utilizing AI in Fertility Health Care"
Related Content
© 2024 MJH Life Sciences

All rights reserved.